Histologically confirmed metastatic or recurrent triple-negative breast cancer (defined as estrogen receptor =< 5%, progesterone receptor =< 5%, HER2-negative via immunohistochemistry [IHC] or fluorescent in situ hybridization [FISH]) [clinicaltrials_resource:0fe27ca5d57c345b89961b312b1bda24]

Histologically confirmed metastatic or recurrent triple-negative breast cancer (defined as estrogen receptor =< 5%, progesterone receptor =< 5%, HER2-negative via immunohistochemistry [IHC] or fluorescent in situ hybridization [FISH]) [clinicaltrials_resource:0fe27ca5d57c345b89961b312b1bda24]

Inclusion Criteria [clinicaltrials_vocabulary:Inclusion-Criteria]
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
http://bio2rdf.org/clinicaltrials_resource:0fe27ca5d57c345b89961b312b1bda24

Histologically confirmed metastatic or recurrent triple-negative breast cancer (defined as estrogen receptor =< 5%, progesterone receptor =< 5%, HER2-negative via immunohistochemistry [IHC] or fluorescent in situ hybridization [FISH]) [clinicaltrials_resource:0fe27ca5d57c345b89961b312b1bda24]

Inclusion Criteria [clinicaltrials_vocabulary:Inclusion-Criteria]
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
http://bio2rdf.org/clinicaltrials_resource:0fe27ca5d57c345b89961b312b1bda24
Bio2RDF identifier
0fe27ca5d57c345b89961b312b1bda24
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0fe27ca5d57c345b89961b312b1bda24
identifier
clinicaltrials_resource:0fe27ca5d57c345b89961b312b1bda24
title
Histologically confirmed metas ...... in situ hybridization [FISH])
@en
inDataset
type
label
Histologically confirmed metas ...... 27ca5d57c345b89961b312b1bda24]
@en